Soluble fiber health claim
This article was originally published in The Tan Sheet
Executive Summary
FDA announces Feb. 6 it proposes to amend the regulation on health claims of soluble fiber reducing the risk of coronary heart disease. The agency proposes to exempt certain foods from the nutrient content requirement of low fat. FDA says, "The exemption would apply if the food exceeds this requirement due to fat content derived from whole oat sources" such as oat bran, rolled oats, whole oat flour and oatrim. The amendment would allow the use of this health claim on some whole oats products that are currently ineligible. The comment deadline is April 23. FDA is amending the health claim in response to a 1995 petition from Pepsico's Quaker Oats Co...
You may also be interested in...
Soluble fiber QHC expanded
More foods rich in soluble fiber can tout their role in reducing the risk of coronary heart disease, according to a May 1 Federal Register notice. FDA expanded the use of the qualified health claim to "any whole oat product that was previously ineligible for the claim" because fat from the whole oat source pushed the food's total fat content past the "low fat" requirement for the claim, the notice says. FDA expanded the claim in response to a petition from PepsiCo's Quaker Oats Co. (1"The Tan Sheet" Feb. 12, 2007, In Brief). The expansion will not cover foods, such as oatmeal cookies, that include other fat sources...
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.